12:00 AM
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GM-CSF-adjuvanted DNA/MVA vaccine: Phase I started

GeoVax began the double-blind, placebo-controlled, dose-escalation, U.S. Phase I HVTN 094 trial to evaluate its GM-CSF-adjuvanted DNA/MVA vaccine in 48 healthy volunteers. The trial is sponsored by the...

Read the full 116 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >